Fusion Historical Income Statement
| FUSN Stock | USD 21.48 0.10 0.47% |
Historical analysis of Fusion PharmaceuticalsI income statement accounts such as Depreciation And Amortization of 1.5 M or Interest Expense of 5.4 M can show how well Fusion PharmaceuticalsInc performed in making a profits. Evaluating Fusion PharmaceuticalsI income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Fusion PharmaceuticalsI's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Fusion PharmaceuticalsInc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fusion PharmaceuticalsInc is a good buy for the upcoming year.
Fusion |
About Fusion Income Statement Analysis
Fusion PharmaceuticalsInc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Fusion PharmaceuticalsI shareholders. The income statement also shows Fusion investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Fusion PharmaceuticalsI Income Statement Chart
Fusion PharmaceuticalsInc Income Statement is one of the three primary financial statements used for reporting Fusion's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Fusion PharmaceuticalsInc revenue and expense. Fusion PharmaceuticalsI Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Fusion PharmaceuticalsI's Total Other Income Expense Net is very stable compared to the past year. As of the 11th of May 2024, Income Tax Expense is likely to grow to about 826.4 K, though Tax Provision is likely to grow to (806.5 K). Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Fusion PharmaceuticalsInc. It is also known as Fusion PharmaceuticalsI overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Fusion PharmaceuticalsI's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Fusion PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, Fusion PharmaceuticalsI's Total Other Income Expense Net is very stable compared to the past year. As of the 11th of May 2024, Income Tax Expense is likely to grow to about 826.4 K, though Tax Provision is likely to grow to (806.5 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 634K | 909K | 1.2M | 1.3M | Total Operating Expenses | 83.5M | 89.5M | 100.0M | 54.3M |
Fusion PharmaceuticalsI income statement Correlations
Click cells to compare fundamentals
Fusion PharmaceuticalsI Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fusion PharmaceuticalsI income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 251K | 2.6M | (118K) | (1.8M) | (849K) | (806.6K) | |
| Net Interest Income | 576K | 327K | 381K | 360K | 3.5M | 3.7M | |
| Depreciation And Amortization | 466K | 6.9M | 634K | 386K | 1.3M | 1.5M | |
| Interest Expense | 2.1M | 327K | 850K | 1.8M | 5.2M | 5.4M | |
| Selling General Administrative | 7.6M | 20.7M | 27.1M | 30.6M | 31.2M | 19.2M | |
| Other Operating Expenses | 18.0M | 37.9M | 83.5M | 89.5M | 101.3M | 54.5M | |
| Operating Income | (18.2M) | (37.9M) | (82.0M) | (88.0M) | (99.2M) | (94.3M) | |
| Net Income From Continuing Ops | (16.2M) | (78.3M) | (81.0M) | (88.0M) | (91.3M) | (86.8M) | |
| Ebit | (18.2M) | (37.9M) | (82.0M) | (88.0M) | (99.2M) | (94.3M) | |
| Research Development | 10.6M | 17.2M | 56.4M | 58.9M | 68.8M | 35.2M | |
| Ebitda | (17.8M) | (31.1M) | (81.4M) | (87.6M) | (97.9M) | (93.0M) | |
| Total Operating Expenses | 18.0M | 37.9M | 83.5M | 89.5M | 100.0M | 54.3M | |
| Reconciled Depreciation | 290K | 482K | 634K | 909K | 1.2M | 1.3M | |
| Income Before Tax | (15.9M) | (75.7M) | (81.2M) | (89.4M) | (94.1M) | (89.4M) | |
| Total Other Income Expense Net | 2.3M | (37.8M) | 850K | (1.4M) | 5.1M | 5.4M | |
| Net Income Applicable To Common Shares | (16.2M) | (79.7M) | (81.0M) | (87.6M) | (78.9M) | (74.9M) | |
| Net Income | (16.2M) | (78.3M) | (81.0M) | (87.6M) | (94.9M) | (90.2M) | |
| Income Tax Expense | 251K | 2.6M | (118K) | (1.8M) | 787K | 826.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Fusion Stock analysis
When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.